Trial Profile

An investigator initiated clinical trial evaluating macimorelin as a potential therapeutic for the treatment of ALS (Lou Gehrig's disease)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Sep 2024 According to a COSCIENS Biopharma media release, the company has decided to discontinue further spend on the preclinical research program to evaluate the potential use of macimorelin for the treatment of amyotrophic lateral sclerosis (ALS), because ALS program has taken far longer and will cost more than was first anticipated and the Company does not have sufficient confidence from the data obtained, to get the anticipated benefits.
06 Aug 2024 According to a COSCIENS Biopharma media release, the Aeterna Zentaris Inc name has been changed to COSCIENS Biopharma.
15 Nov 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com